Dr. Muhammad Umair Mushtaq is an Assistant Professor of Medicine, Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Medical Center. He completed a Hematology and Oncology fellowship at the University of Wisconsin Hospitals and Clinics. He earned his medical degree from Allama Iqbal Medical College and completed his residency at Cook County Health and Hospitals System.
Dr. Mushtaq is a clinical investigator with a focus on hematologic malignancies, hematopoietic stem cell transplantation, cellular therapy, immunotherapy, and global health. He has a long history of research productivity with over 1000 citations.
Comparison of Salvage Chemotherapy Regimens and Prognostic Significance of Minimal Residual Disease in Relapsed/Refractory Acute Myeloid Leukemia
Gender Disparities in the National Institutes of Health Funding for Hematologic Malignancies and Cellular Therapies
Impact of COVID-19 in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis
Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
Outcomes After Venetoclax With Hypomethylating Agents in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis
Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis.
Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysis.
Simultaneous acute myeloid leukemia, multiple myeloma, and amyloidosis.
Tumor Matrix Remodeling and Novel Immunotherapies: The Promise of Matrix-Derived Immune Biomarkers
Use of Endpoints in Phase III Randomized Controlled Trials for Acute Myeloid Leukemia over the Last 15 Years: A Systematic Review Journal
Versican proteolysis predicts immune effector infiltration and post-transplant survival in myeloma.
A Phase II Study of Expanded/Activated Gamma-Delta T-cells after Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplant Cyclophosphamide
A phase I/II Study evaluating the safety and the efficacy of SMART101 Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell transplantation in pediatric and adult patients with acute leukemia
A Phase lb, Open-Label, Randomized, Dose-Finding, Multicenter Study To Evaluate The Safety, Efficacy, And Pharmacokinetics Of GDC-8264 In Combination With Standard Of Care In The Treatment Of Acute Graft-Versus-Host Disease In Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (GA43861)
Impact of Microbiota on outcomes after chimeric antigen receptor (CAR) T-cell therapy
Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion before Tumor-Infiltrating Lymphocytes Therapy with Lifileucel in Metastatic Melanoma